OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated ...

IMUNON (IMNN) announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of ...

Ardena Acquired Catalent’s Somerset, NJ, oral solids development and small-scale drug product manufacturing facility for an undisclosed price, in a deal completed in February. In Somerset, expanded ...

Traditional microbial expression systems can be advanced through improved plasmid replication, target gene transcription, ...

LONDON, GREATER LONDON, UNITED KINGDOM, September 15, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Syndromic Multiplex Diagnostics Market Through 2025? The market size for syndromic ...